Promega's cell-based Mitochondrial Toxglo Assay enables researchers to quickly profile large compound libraries or medicinal modifications for their effects on mitochondria.
It does this by allowing them to distinguish primary mitochondrial dysfunction from secondary cytotoxic events in a single well via a sequential-addition, multiplexed assay chemistry.
The Mitochondrial Toxglo Assay is based on the differential measurement of biomarkers associated with changes in cell-membrane integrity and cellular ATP levels during short xenobiotic exposure periods.
Its sequential 'add-mix-read' format has been developed to enable researchers to quickly assess potential mitochondrial liabilities in less than one hour.
The assays are performed directly in cell-culture microwell plates and data captured using standard multimode detection instrumentation.
The assay can be automated and scaled to meet throughput needs for 96- and 384-well plate formats.
